The dominant story in U.S. equities through early 2026 is a rotation away from mega-cap technology and toward domestically oriented small-cap companies, driven by three structural tailwinds that are reshaping the risk-reward calculus across the asset class.
The Federal Reserve delivered 75 basis points of rate cuts in late 2025, reducing borrowing costs for smaller companies that carry proportionally more floating-rate debt than their large-cap peers. Domestic fiscal policy has reinforced that tailwind, with the One Big Beautiful Bill Act restoring 100% bonus depreciation and domestic R&D expensing, measures that disproportionately benefit capital-intensive smaller firms. On the earnings side, analysts forecast median small-cap earnings growth of 18.4% for 2026, nearly double the S&P 500 consensus of 9.8%. A hawkish Fed pause in March has introduced near-term turbulence, and volatility is an inherent feature of this asset class. The broader valuation and rotation argument is addressed in the closing section of this piece. Selectivity remains essential.
10 Small Caps Worth Watching
1. NioCorp Developments Ltd. (NASDAQ: NB)
Source: NioCorp Developments Ltd.
Sector: Critical Minerals
Key story: NioCorp is developing the Elk Creek niobium, scandium, and titanium project in Nebraska, the highest-grade niobium resource in North America per the company. In February 2026, it commenced construction of a $44.6 million mine portal and has raised approximately $500 million in equity capital since 2025, while pursuing a $780 million EXIM debt commitment to complete the estimated $1.2 billion project.
Why investors are watching: The White House and EXIM launched "Project Vault" in early 2026, a public-private critical minerals reserve initiative backed by $1.67 billion from General Motors, Boeing, Google, and others, directly elevating the strategic profile of domestic niobium and scandium supply. H.C. Wainwright carries a Buy with an $11.25 price target. NB was trading near $4.59 on March 26, 2026, with a 52-week range of $1.83–$12.58.
2. Nova Minerals Ltd. (NASDAQ: NVA)
Source: Nova Minerals Ltd.
Sector: Gold and Antimony Exploration
Key story: Nova holds a JORC-compliant 9.9 million ounce global gold resource at its Estelle Project in Alaska's Tintina Gold Belt, alongside multiple drill-ready antimony prospects. Its antimony strategy is fully funded by a $43.4 million U.S. Department of War award, with domestic production targeted for late 2026 or 2027.
Why investors are watching: Gold continues to trade near historic highs amid persistent macro uncertainty. On the antimony side, China has banned all exports of the mineral to the United States, which controls roughly 60% of global supply, making domestic alternatives an active national security priority. An independent report by RFC Ambrian (February 2025) identified Estelle as one of only nine projects globally with near-term antimony production potential. NVA was trading near $5.82 on March 25, 2026, with a market cap of approximately $220 million.
3. Sharon AI, Inc. (NASDAQ: SHAZ)
Source: Sharon AI, Inc.
Sector: AI Infrastructure
Key story: SharonAI is an Australian "Neocloud" that listed on Nasdaq on February 18, 2026 via a $125 million IPO backed by Oaktree Capital Management and Two Seas Capital. The company provides GPU-as-a-service, sovereign AI clusters, and cloud compute infrastructure, with recent partnerships including a Cisco AI "factory" collaboration and a supply chain agreement with World Wide Technology.
Why investors are watching: Demand for independent, scalable GPU compute outside the hyperscaler ecosystem continues to expand as AI workloads proliferate globally. SharonAI is a newly public company with a limited operating history, and execution risk is material. SHAZ was trading near $24.31 on March 25, 2026, with a market cap of approximately $392 million.
4. Connect Biopharma Limited (NASDAQ: CNTB)
Source: Connect Biopharma Holdings Ltd.
Sector: Biopharmaceuticals — Respiratory Inflammation
Key story: Connect is advancing rademikibart, a monoclonal antibody targeting IL-4Ra, for acute asthma and COPD exacerbations. Phase 2b data presented at ERS 2025 showed a 507 mL improvement in FEV1 at Week 24 in high-biomarker patients. Topline data from two Phase 2 Seabreeze STAT studies are expected mid-2026, with $54.8 million in cash funding operations into 2027.
Why investors are watching: The mid-2026 data readouts represent a clearly defined binary catalyst in a large and underserved respiratory market. BTIG and Lake Street both carry Buy ratings, with a median analyst price target of $7.50 against a current price near $2.87.
5. 908 Devices (NASDAQ: MASS)
Source: 908 Devices Inc.
Sector: Analytical Instrumentation
Key story: 908 Devices makes handheld and desktop mass spectrometry devices for forensics, defense, and biopharma applications. The company reported preliminary full-year 2025 revenue of approximately $56 million, representing 17% growth, and beat Q4 EPS estimates by $0.17.
Why investors are watching: The VIPER and Explorer devices are positioned as primary growth drivers for 2026, with management guiding toward continued revenue expansion. Government contract exposure adds both opportunity and near-term risk, management flagged potential delays of up to $4 million from federal disruptions. The average analyst price target is $10.00. MASS carries a market cap of approximately $234 million.
6. 8x8 Inc. (NASDAQ: EGHT)
Source: 8x8 Inc.
Sector: Cloud Communications
Key story: 8x8 provides a unified CCaaS, UCaaS, and CPaaS platform. For fiscal Q3 ended December 31, 2025, the company reported $185.1 million in total revenue and its 20th consecutive quarter of positive operating cash flow, with adjusted EPS of $0.12, ahead of consensus. The company has reduced debt by $224 million since August 2022.
Why investors are watching: 8x8 Engage, its distributed workforce CX product, reached general availability in March 2026 with customer adoption running more than 150% year over year, a concrete product-traction signal in a competitive market. Rosenblatt Securities maintains a Buy. EGHT was trading near $1.86 with a market cap of approximately $238 million.
7. A2Z Smart Technologies Corp. (NASDAQ: AZ)
Source:A2Z Smart Technologies Corp.
Sector: Retail Automation
Key story: A2Z's flagship product is the Cust2Mate smart shopping cart, which enables in-cart scanning and payment, eliminating the traditional checkout lane. Management is targeting deployment of over 30,000 carts across eight global retailers by 2026, backed by existing purchase orders for at least 11,000 units.
Why investors are watching: Rising labor costs are accelerating retailer interest in automated checkout solutions. The company entered toy retail via a Toys "R" Us order in January 2026 and launched a Retail Media Division, adding a recurring revenue component to its hardware model. AZ was trading near $5.53 with a market cap of approximately $182 million.
8. a.k.a. Brands Holding Corp. (NYSE: AKA)
Source: a.k.a Brands Holding Corp.
Sector: Digital Fashion E-Commerce
Key story: a.k.a. Brands operates Princess Polly, Culture Kings, Petal & Pup, and mnml, digital-first fashion labels targeting social-media-native consumers. Q4 2025 net sales were $164 million, up 3.1% year over year, with trailing twelve-month revenue of approximately $600 million.
Why investors are watching: At current prices, the stock trades at a price-to-sales ratio near 0.16x, a material discount to comparable digital retail peers. The company completed a credit facility refinancing in 2025 that extended its debt maturity profile, reducing near-term balance sheet pressure. AKA carries a market cap of approximately $97 million.
9. Gold.com Inc. (NYSE: GOLD) (Formerly A-Mark Precious Metals, Inc.)
Source: A-Mark Precious Metals Inc.
Sector: Precious Metals Trading
Key story: Formerly A-Mark Precious Metals, the company rebranded and relisted on NYSE as GOLD effective December 2, 2025, following its acquisition of Monex Deposit Company. Gold.com operates across wholesale, direct-to-consumer, and secured lending segments. For fiscal Q1 2026, it reported revenue of $3.68 billion, up 36% year over year, with gross profit growing 68% to $72.9 million.
Why investors are watching: Gold continues to trade near all-time highs amid macro uncertainty and dollar volatility, driving elevated retail demand for physical bullion and supporting higher transaction volumes across all three of the company's business segments. GOLD was trading near $29.25 with a consensus Buy and a $31.50 analyst price target.
10. AbCellera Biologics (NASDAQ: ABCL)
Source: AbCellera Biologics Inc.
Sector: AI-Driven Antibody Discovery
Key story: AbCellera combines an AI-powered antibody discovery platform with an internal clinical pipeline spanning 19 molecules in trials across its partner network. The company reported $75.1 million in full-year 2025 revenue and holds approximately $700 million in available liquidity, sufficient, per management, to fund pipeline activities beyond the next three years.
Why investors are watching: Two proprietary programs, ABCL635 (vasomotor symptoms of menopause) and ABCL575 (T-cell-mediated autoimmune conditions), are both expected to produce Phase 1 topline readouts in H2 2026, providing a defined catalyst window. BMO Capital maintains a Buy. ABCL carries a market cap of approximately $1.0 billion and a consensus analyst price target of $7.75.
Big Market Insight
Large caps continue to dominate the headline indices, but small caps are trading at historically cheap valuations, and that gap has historically been a reliable setup for a multi-year rotation. Entering 2026, the Russell 2000 was trading at a 31% forward P/E discount to the S&P 500, a spread that CME Group has noted is among the widest on record across price-to-earnings, price-to-sales, and price-to-book metrics.
When gaps of this magnitude have appeared historically, the pattern has been consistent: institutional liquidity rotates toward cheaper assets, smaller names re-rate, and the discount compresses over a one-to-three year period. CME Group's data shows the Russell 2000 outperformed the S&P 500 by 99% in the four years following the dot-com peak and by 28% through the post-2008 recovery, both periods that began from comparably wide valuation discounts. With median small-cap earnings growth forecast at 18.4% for 2026 against a 9.8% S&P 500 consensus, the fundamental case for that rotation is building.